Raymond James analyst Rahul Sarugaser initiated coverage of Point Biopharma with an Outperform rating and $10 price target. Point is a precision oncology company focused on the clinical development and commercialization of radiopharmaceuticals for the treatment of cancer, Sarugaser tells investors in a research note. The analyst believes therapeutic radiopharma "is on the verge of a material inflection."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- Point Biopharma initiated with an Outperform at SVB Securities
- POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
- Point Biopharma releases new preclinical data on 177Lu-PNT6555
- Point Biopharma price target lowered to $14 from $17 at Piper Sandler
- POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
